Drugs /

nk-92

Back to Drugs List

Overview

NCI Definition [1]:
A proprietary, human cytotoxic cell line composed of allogeneic, activated, interleukin-2 (IL-2) dependent-natural killer cells derived from a 50-year old male patient with rapidly progressive non-Hodgkin's lymphoma, with potential antineoplastic activity. As NK-92 cells are devoid of killer inhibitory receptors (KIRs; also called killer cell immunoglobulin-like receptors), which are negative regulators of NK cell activity, cancer cells are unable to suppress the cancer cell killing ability of the NK-92 cells. Upon infusion of the allogeneic NK cell line NK-92, the NKs recognize and bind to tumor cells. This leads to the secretion and release of perforins, granzymes, cytokines and chemokines, which results in cancer cell lysis and apoptosis. In addition, NK-92 cells express high affinity Fc receptors, which bind to therapeutic antibodies; therefore, this agent can enhance antibody dependent cellular cytotoxicity (ADCC) of co-administered therapeutic antibodies.

Clinical Trials

View Clinical Trials for nk-92

Nk-92 has been investigated in 4 clinical trials, of which 2 are open and 2 are closed. Of the trials investigating nk-92, 1 is phase 1 (0 open) and 3 are phase 2 (2 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for nk-92 clinical trials.

Acute biphenotypic leukemia, acute lymphoblastic leukemia, and acute myeloid leukemia are the most common diseases being investigated in nk-92 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Nk-92
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Nk-92
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating nk-92 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
hank, allogeneic natural killer cell line nk-92, nk-92 cells
NCIT ID [1]:
C117231

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.